Demonstrating value has become one of the biggest challenges facing life sciences companies, as payers and health technology assessment bodies look beyond regulatory approval to long-term outcomes, real-world performance and systemwide impact. In a sponsored episode of The Top Line, leaders from RTI Health Solutions discuss how health economics and outcomes research and real-world evidence have moved from supplementary analyses to core inputs in pricing, access and reimbursement decisions. With tighter budgets and greater scrutiny, decision-makers increasingly want to understand not just whether a therapy works, but how it performs for real patients over time and what it means for healthcare systems as a whole.
The conversation explores how translating complex data into clear, audience-focused narratives can determine whether evidence resonates or falls flat. Panelists highlight the importance of aligning HEOR and real-world evidence with the clinical story, tailoring messages for payers, clinicians and patients, and integrating design early to make insights easier to understand and act on. From visual abstracts to plain-language summaries, the discussion underscores why credibility today comes from relevance and clarity rather than volume. To hear how these strategies are being applied—and what they mean for the future of evidence communication—listen to the full episode of The Top Line.